

# Bostonsight publishes groundbreaking study highlighting PROSE® lens utilization for drug delivery

NEEDHAM, MA, UNITED STATES,  
November 21, 2024 /

EINPresswire.com/ -- BostonSight® announced it has published a groundbreaking [study](#): “Utilizing [PROSE](#) as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease: A Pilot Study” in the journal *Clinical Ophthalmology*.



“The publication of this landmark open-label, prospective, non-comparative clinical trial highlights the investigative approach, concepts, and many important scientific questions regarding the use of PROSE® or scleral lenses as a drug delivery device,” said Daniel Brocks, MD, Chief Medical Officer at BostonSight and the study’s research lead.

“

Ultimately, we anticipate that our research in this area will lead to additional ocular management strategies to improve ocular health and the lives of our patients.”

*Dr. Daniel Brocks, Chief  
Medical Officer*

PROSE treatment uses highly customized scleral lenses to treat patients with corneal irregularities and ocular surface diseases. A scleral lens rests on the white of the eye (the sclera) and vaults over the cornea, creating a new surface over the damaged cornea. The space between the cornea and the lens is filled with preservative-free saline, creating

a fluid reservoir that bathes the cornea continuously to promote comfort, healing, and relief.

BostonSight conducted testing using Cyclosporine 0.05%, known commercially as [Restasis](#)®, in the scleral lens reservoir for the treatment of dry eye disease.

“Ultimately, we anticipate that our research in this area will lead to additional ocular management strategies to improve ocular health and the lives of our patients,” said Brocks.

With an integrated team of clinicians, clinical researchers, and engineers at the top of their respective fields, a robust clinical network, and a state-of-the-art manufacturing lab, BostonSight

is an ideal research partner for the design and execution of clinical trials.

Read the study here: [https://www.dovepress.com/articles.php?article\\_id=97126](https://www.dovepress.com/articles.php?article_id=97126)

#### About BostonSight®

BostonSight® is a nonprofit healthcare organization that advances the treatment of corneal irregularities and ocular surface disease through specialty lenses. PROSE® is BostonSight's medical treatment for the most severe ocular surface diseases and BostonSight SCLERAL® is a commercially available scleral lens used by optometrists worldwide. BostonSight's ongoing commitment to research and achieving optimal patient outcomes through innovative scleral lens design, education, and technology have saved the sight of thousands of people around the world. Learn more at [www.bostonsight.org](http://www.bostonsight.org).

Michele Hart  
BostonSight  
mhart@bostonsight.org

---

This press release can be viewed online at: <https://www.einpresswire.com/article/762376773>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.